SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.
Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
DRUG: SHR1459 ；YY-20394|DRUG: SHR1459 ；YY-20394|DRUG: Gemcitabine-Oxaliplatin
Stage 1: MTD （Maximum tolerated dose）or RP2D（Recommended Phase II Dose) of SHR1459 and YY-20394;, Minimum observation period is 28 days for the maximum dose cohort|Stage 2: Overall response rate (ORR), 8 weeks after last patient first visit (LPFV)
Incidence of Adverse Events, At every treatment and follow up visit until disease progression. Expected to be for up to 6 months
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.